Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | B3GNT2 | Q9NY97 | 4/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263432 | 0.93 | MAPK1 (0.42) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL269225 | 0.83 | KMT2A (0.42) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL263879 | 0.83 | KMT2A (0.42) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL269762 | 0.80 | PDE2A (0.45) | NR1H4 | |
| SCHEMBL264134 | 0.80 | NR1H4 (0.47) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL1754180 | 0.79 | LMNA (0.47) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL264194 | 0.78 | SMYD3 (0.44) | MAPK1MEN1LMNAKMT2A | |
| SCHEMBL1753790 | 0.77 | HPGD (0.47) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL1643203 | 0.76 | LMNA (0.41) | MAPK1MEN1LMNAKMT2AROCK2 | |
| SCHEMBL262974 | 0.76 | ROCK2 (0.43) | ROCK2ROCK1B3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | MAPK1 1388/4885MEN1 4051/4885LMNA 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.